Tyvaso (treprostinil) Disease Interactions
There is 1 disease interaction with Tyvaso (treprostinil):
Treprostinil (Includes Tyvaso) ↔ Hepatic Impairment
Severe Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction
The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C). There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients. It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).
Tyvaso (treprostinil) drug Interactions
There are 687 drug interactions with Tyvaso (treprostinil)
More about Tyvaso (treprostinil)
- Tyvaso Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- 10 Reviews
- Drug class: agents for pulmonary hypertension
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.